CompletedNot Applicable

Use of Copeptin in Diabetes Insipidus

Switzerland156 participantsStarted 2013-07

Plain-language summary

Prospective evaluation of the novel biomarker copeptin in the differential diagnosis of diabetes insipidus against the standard diagnostic test methods.

Who can participate

Age range16 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Polyuria or/and Polydipsia or/and therapy with synthetic adenovirus proteinase (AVP) derivate * Urine osmolality \<800mOsm/kgH20 Exclusion Criteria: * Polyuria due to diabetes mellitus * Hypokalemia * Hyperkalemia (\>5mmol/l) * Hypercalcemia * Kidney disease (min.: glomerular filtration rate (GFR) 60ml/min/1.73m2) * Pregnancy * Hyponatremia \>135mmol/L * Hypernatremia \>145mmol/L * Hypo- or hypervolemia * uncorrected adrenal or thyroidal deficiency * Cardia failure * Epilepsia * Uncontrolled hypertension

What they're measuring

Overall diagnostic accuracy

Timeframe: beginning and end of protocol, up to 9hours

Trial details

NCT IDNCT01940614

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-06

View on ClinicalTrials.gov More Diabetes Insipidus trials